Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

Your First-Line Treatment Options

At a Glance

The goal of first-line DLBCL treatment is a complete and permanent cure. The standard regimen is R-CHOP, though alternatives like Pola-R-CHP or DA-EPOCH-R may be used depending on your specific subtype. Treatment requires careful monitoring for severe side effects, especially infections.

Because Diffuse Large B-Cell Lymphoma (DLBCL) is fast-growing, your medical team will move quickly to start your treatment—often within days or weeks of your diagnosis [1]. The goal of first-line treatment is to achieve a complete and permanent cure [2].

Standard Frontline Regimens

Your doctor will choose a regimen based on your specific lymphoma subtype, your overall health, and your risk score.

R-CHOP

For decades, R-CHOP has been the gold standard for treating DLBCL [3]. It is a combination of five drugs:

  • R: Rituximab (an antibody that targets CD20 on B-cells) [4]
  • C: Cyclophosphamide (an alkylating agent)
  • H: Hydroxydaunorubicin (also known as Doxorubicin)
  • O: Oncovin (the brand name for Vincristine)
  • P: Prednisone (a steroid)

Pola-R-CHP

This is a newer option that replaces the “O” (Vincristine) with a drug called Polatuzumab vedotin [5]. It is often considered for patients with the ABC subtype or those with higher risk scores [5][6].

DA-EPOCH-R

This is a more intensive “dose-adjusted” regimen [7]. It is frequently recommended for “Double-Hit” or “Triple-Hit” lymphomas, which can be more resistant to standard R-CHOP [8][9].

Preparing for Critical Side Effects

While chemotherapy causes common symptoms like hair loss and fatigue, you must be prepared for more significant impacts:

Infection Risk and Neutropenia

Chemotherapy will significantly weaken your immune system by lowering your white blood cell count (a condition called neutropenia).

  • The Risk: Even a minor infection can become life-threatening very quickly.
  • The Action: A fever is a medical emergency. If your temperature reaches 100.4°F (38°C) or higher, or if you experience severe chills or uncontrolled nausea, you must call your doctor immediately or go to the emergency room [10].

Steroid Side Effects (The “P” - Prednisone)

High-dose steroids can cause some of the most jarring daily side effects. You may experience severe insomnia, rapid mood swings, a ravenous appetite, and spikes in blood sugar. Knowing this in advance can help you mentally prepare for these emotional and physical fluctuations.

Heart and Nerve Health

  • The “H” (Doxorubicin): This drug can weaken the heart muscle [11]. You will have an echocardiogram before starting [12].
  • The “O” (Vincristine or Polatuzumab): These can cause peripheral neuropathy (nerve damage in hands and feet) [12][13]. Report any “pins and needles” or numbness to your team immediately [14].

Fertility Preservation

Because DLBCL affects many younger adults and chemotherapy can impact fertility, it is crucial to ask your oncologist about fertility preservation options before starting your first cycle.

What to Expect During a Cycle

Most treatments are given in cycles (usually every 21 days) [15]. You will likely receive 6 cycles in total. During a 21-day cycle, you will typically feel your worst during days 3-7 as the drugs take full effect, and then slowly bounce back and regain your energy before the next cycle begins [3].

If standard options don’t completely eliminate the cancer, there are still excellent options available. See When the First Treatment Doesn’t Work.

Common questions in this guide

What is the standard first-line treatment for DLBCL?
The traditional gold standard treatment is R-CHOP, a combination of five drugs including rituximab and chemotherapy. Depending on your specific lymphoma subtype and risk factors, your doctor might also recommend other regimens like Pola-R-CHP or DA-EPOCH-R.
What should I do if I get a fever during DLBCL chemotherapy?
A fever during chemotherapy is considered a medical emergency because the treatment severely weakens your immune system. If your temperature reaches 100.4°F (38°C) or higher, or if you have severe chills, you must contact your doctor immediately or go to the emergency room.
Will DLBCL treatment affect my heart?
Certain chemotherapy drugs used in DLBCL treatment, such as doxorubicin, can potentially weaken the heart muscle. Your medical team will typically perform an echocardiogram before you start treatment to ensure your heart is healthy enough to handle the regimen.
Why might my doctor recommend DA-EPOCH-R instead of R-CHOP?
DA-EPOCH-R is a more intensive, dose-adjusted regimen that is often recommended for Double-Hit or Triple-Hit lymphomas. These specific subtypes can be more resistant to standard R-CHOP, requiring a stronger initial treatment approach.
What are the side effects of the steroids used in DLBCL treatment?
High-dose steroids like prednisone are a key part of your treatment and can cause jarring daily side effects. You may experience severe insomnia, rapid mood swings, a ravenous appetite, and spikes in blood sugar during the days you take the medication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my IPI score and subtype (GCB vs. ABC), which frontline regimen—R-CHOP or Pola-R-CHP—do you recommend for me?
  2. 2.Does my pathology show a 'double-hit' status that would make DA-EPOCH-R a better option than R-CHOP?
  3. 3.What is the plan for monitoring my heart health before and during treatment with doxorubicin?
  4. 4.How often will we check in about nerve symptoms like tingling or numbness in my hands and feet?
  5. 5.How soon are we planning to start my first cycle of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.

    Chien HC, Morreall D, Patil V, et al.

    Future oncology (London, England) 2021; (17(4)):411-422 doi:10.2217/fon-2020-0522.

    PMID: 33115291
  2. 2

    Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

    Coiffier B, Sarkozy C

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):366-378 doi:10.1182/asheducation-2016.1.366.

    PMID: 27913503
  3. 3

    Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

    Liu Y, Barta SK

    American journal of hematology 2019; (94(5)):604-616 doi:10.1002/ajh.25460.

    PMID: 30859597
  4. 4

    Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

    Freeman CL, Sehn L

    Current oncology reports 2018; (20(12)):103 doi:10.1007/s11912-018-0748-0.

    PMID: 30483893
  5. 5

    Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

    Morschhauser F, Salles G, Sehn LH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(35)):3698-3705 doi:10.1200/JCO-25-00925.

    PMID: 40991874
  6. 6

    Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.

    Sheng Z, Li D, Chen B, et al.

    Annals of hematology 2023; (102(5)):1011-1017 doi:10.1007/s00277-023-05161-1.

    PMID: 36947214
  7. 7

    Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

    David RJ, Baran A, Loh KP, et al.

    Clinical lymphoma, myeloma & leukemia 2018; (18(12)):781-787 doi:10.1016/j.clml.2018.08.014.

    PMID: 30262330
  8. 8

    DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.

    Mitobe M, Kawamoto K, Suzuki T, et al.

    Journal of clinical and experimental hematopathology : JCEH 2021; (61(1)):42-47 doi:10.3960/jslrt.20043.

    PMID: 33551436
  9. 9

    Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India.

    Moharana L, Dasappa L, Babu S, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2022; (38(1)):15-23 doi:10.1007/s12288-021-01427-8.

    PMID: 35125708
  10. 10

    Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features.

    Dholaria B, Vanegas YAM, Diehl N, et al.

    Clinical hematology international 2020; (2(3)):117-124 doi:10.2991/chi.d.200410.001.

    PMID: 34595452
  11. 11

    An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.

    Walji M, Assouline S

    Expert review of hematology 2020; (13(9)):933-942 doi:10.1080/17474086.2020.1795828.

    PMID: 32700586
  12. 12

    FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.

    Sarraf Yazdy M, Kasamon YL, Gu W, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(24)):5521-5526 doi:10.1158/1078-0432.CCR-24-1729.

    PMID: 39404868
  13. 13

    Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

    Tilly H, Morschhauser F, Bartlett NL, et al.

    The Lancet. Oncology 2019; (20(7)):998-1010 doi:10.1016/S1470-2045(19)30091-9.

    PMID: 31101489
  14. 14

    Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?

    Ngu H, Takiar R, Phillips T, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-14 doi:10.1200/EDBK_349307.

    PMID: 35594501
  15. 15

    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

    Tilly H, Morschhauser F, Sehn LH, et al.

    The New England journal of medicine 2022; (386(4)):351-363 doi:10.1056/NEJMoa2115304.

    PMID: 34904799

This page provides general information about first-line chemotherapy regimens for DLBCL. Always consult your oncologist to determine the best treatment plan for your specific subtype and health status.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.